NCT02071355View on ClinicalTrials.gov

A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Healthy
Interventions
DRUG

TMC435 100 mg

Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.

DRUG

TMC435 150 mg

Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.

Trial Locations (1)

Unknown

Beijing

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02071355 - A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter